Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908683 · ClinicalTrials.gov registry record · Phase 3
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 25,236
- Enrollment target
NCT04908683 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 25,236 participants.
The verdict
NCT04908683, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25,236 participants
- Enrollment target
Study Summary
The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) when compared to placebo in adults aged 60 years and above.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25,236 participants |
| Start Date | 2021-07-21 |
| Est. Completion | 2023-07-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908683
The ClinicalTrials.gov registry entry for NCT04908683 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25,236 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04908683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908683 about?
NCT04908683 is a clinical study titled "A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older". The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRT...
What is the current status of trial NCT04908683?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25,236 participants. The study started on 2021-07-21. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT04908683?
The interventions under investigation include: Placebo (BIOLOGICAL), Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF (BIOLOGICAL).
Who is sponsoring clinical trial NCT04908683?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.